PMID- 27493970
OWN - NLM
STAT- MEDLINE
DCOM- 20170609
LR  - 20190723
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2016
DP  - 2016
TI  - The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in 
      Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective 
      Study.
PG  - 2909436
LID - 10.1155/2016/2909436 [doi]
LID - 2909436
AB  - Background. The aim of this study was to validate the impact of type 2 diabetes 
      (T2D) on the platelet reactivity in patients with acute ST elevation myocardial 
      infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. 
      Methods. A pilot prospective study was performed. Totally 67 patients were 
      enrolled. 21 patients had T2D. Among all study population, 33 patients received 
      clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor 
      blocker therapy had been tested in two time intervals using light transmission 
      aggregometry with specific inducer and vasodilator-stimulated phosphoprotein 
      phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant 
      differences in platelet aggregability among T2D and nondiabetic (ND) group. The 
      platelet reactivity index of VASP-P did not differ significantly between T2D and 
      ND group (59.4 +/- 30.9% versus 60.0 +/- 25.2% and 33.9 +/- 25.3% versus 38.6 +/- 29.3% 
      in second testing). The number of ADP receptor blocker nonresponders did not 
      differ significantly between T2D and ND patients. The time interval from ADP 
      receptor blocker loading dosing to the blood sampling was similar in T2D and ND 
      patients in both examinations. Conclusion. This prospective study did not confirm 
      the higher platelet reactivity and higher prevalence of ADP receptor blocker 
      nonresponders in T2D acute STEMI patients.
FAU - Samos, Matej
AU  - Samos M
AUID- ORCID: 0000-0002-5561-2560
AD  - Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, 
      Comenius University in Bratislava, 03659 Martin, Slovakia.
FAU - Fedor, Marian
AU  - Fedor M
AD  - National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood 
      Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in 
      Bratislava, 03659 Martin, Slovakia.
FAU - Kovar, Frantisek
AU  - Kovar F
AD  - Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, 
      Comenius University in Bratislava, 03659 Martin, Slovakia.
FAU - Galajda, Peter
AU  - Galajda P
AD  - Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, 
      Comenius University in Bratislava, 03659 Martin, Slovakia.
FAU - Bolek, Tomas
AU  - Bolek T
AD  - Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, 
      Comenius University in Bratislava, 03659 Martin, Slovakia.
FAU - Stanciakova, Lucia
AU  - Stanciakova L
AD  - National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood 
      Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in 
      Bratislava, 03659 Martin, Slovakia.
FAU - Fedorova, Jana
AU  - Fedorova J
AD  - HemoMedika, Centre of Thrombosis and Hemostasis, 03601 Martin, Slovakia.
FAU - Stasko, Jan
AU  - Stasko J
AD  - National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood 
      Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in 
      Bratislava, 03659 Martin, Slovakia.
FAU - Kubisz, Peter
AU  - Kubisz P
AD  - National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood 
      Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in 
      Bratislava, 03659 Martin, Slovakia.
FAU - Mokan, Marian
AU  - Mokan M
AD  - Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, 
      Comenius University in Bratislava, 03659 Martin, Slovakia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160717
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Drug Therapy, Combination
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Pilot Projects
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Function Tests
MH  - Prasugrel Hydrochloride/*therapeutic use
MH  - Prospective Studies
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - ST Elevation Myocardial Infarction/complications/*therapy
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
PMC - PMC4967473
EDAT- 2016/08/06 06:00
MHDA- 2017/06/10 06:00
PMCR- 2016/07/17
CRDT- 2016/08/06 06:00
PHST- 2016/03/23 00:00 [received]
PHST- 2016/05/27 00:00 [revised]
PHST- 2016/06/22 00:00 [accepted]
PHST- 2016/08/06 06:00 [entrez]
PHST- 2016/08/06 06:00 [pubmed]
PHST- 2017/06/10 06:00 [medline]
PHST- 2016/07/17 00:00 [pmc-release]
AID - 10.1155/2016/2909436 [doi]
PST - ppublish
SO  - J Diabetes Res. 2016;2016:2909436. doi: 10.1155/2016/2909436. Epub 2016 Jul 17.